



# Elevidys in India

*The CDSCO named-patient coordination pathway — indicative 2026*

RARE DISEASE · AAVRH74 GENE THERAPY FOR DMD

## The clinical situation

Elevidys (delandistrogene moxeparvovec-rokl) is a one-time AAVrh74-based gene therapy delivering an engineered micro-dystrophin transgene for ambulant and non-ambulant Duchenne muscular dystrophy patients aged 4 years and older with a confirmed DMD mutation. Manufactured by Sarepta. Single weight-dosed IV infusion with peri-infusion corticosteroid prophylaxis. Transaminase, CK, platelet, and troponin monitoring weekly for the first three months then per schedule.

### The pathway, 5 steps

- 1 Consultation & DMD genotyping.** Your paediatric neurology team confirms DMD mutation profile, age, weight, anti-AAVrh74 antibody titre, and ambulatory status.
- 2 Baseline assessment.** Transaminases, CK, platelets, troponin-I, NSAA/motor function measures, and cardiac/pulmonary baseline.
- 3 CDSCO named-patient application.** Clinical rationale, genotype report, weight, and infusion-centre attestation filed under personal-use import.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates the dose through our US-licensed DSCSA-compliant specialty wholesale partner; ultra-low cold-chain to the infusion centre.
- 5 Infusion & post-dose monitoring.** Paediatric team infuses at a qualified centre with corticosteroid prophylaxis; weekly labs for the first three months per FDA labelling.

### Indicative economics

**Reference US cash-pay range:** USD 3,100,000–3,350,000 as a one-time product cost (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**6–10 weeks** from a complete CDSCO application to infusion, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your paediatric neurology team and CDSCO review, keyed to DMD genotype and age/weight. **Logistics.** Ultra-low cold-chain shipment with importer-of-record handling to the infusion centre. **Concierge case lead.** Named point of contact for the family and care team. **We are a coordinator** — not the prescriber, not the infusion centre. All clinical decisions remain with your treating paediatric neurologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Elevidys × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/elevidys-india.html](https://reservemed.com/access-guides/elevidys-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team